What were the main drivers of Stryker's revenue growth in 2003?

Stryker's revenue growth in 2003 was driven by a combination of increased unit volume and changes in product mix (12%), higher selling prices (2%), favorable foreign currency exchange rate movements (5%), and contributions from acquired businesses (1%). Both the Orthopaedic Implants and MedSurg Equipment segments experienced strong shipment increases.

How did Stryker manage its debt and financial resources?

Stryker significantly reduced its outstanding debt in 2003, with total borrowings declining from $501.7 million to $26.1 million. This was achieved through strong cash flow from operations and strategic use of its accounts receivable securitization facility. The company also ended the year with substantial borrowing capacity available under its credit facilities.

What is the significance of the OP-1 product for Stryker?

OP-1 (Osteogenic Protein-1) is a bone growth factor product that Stryker has invested in for two decades. While facing initial regulatory hurdles, it received Humanitarian Device Exemption approval in the US and market authorization in Europe, Australia, and Canada for specific long-bone nonunion indications. Stryker is also actively pursuing its development for spinal indications, indicating its strategic importance for future growth.

What are Stryker's key segments and how did they perform?

Stryker operates in two main reportable segments: Orthopaedic Implants and MedSurg Equipment. In 2003, the Orthopaedic Implants segment saw sales increase by 23% to $2.09 billion, driven by reconstructive, trauma, and spinal implants. The MedSurg Equipment segment grew by 18% to $1.31 billion, with increases in powered surgical instruments, endoscopic products, hospital beds, and navigation systems. Additionally, Physical Therapy Services contributed $223 million in revenue.

SYK 10-K FY2003 Annual Report — Revenue, Net Income, EPS

Summary

Stryker Corporation's 2003 Form 10-K report showcases a company with robust growth and a diversified product portfolio in the orthopaedics and medical technology sectors. The company achieved a significant 20% increase in net sales, reaching $3.6 billion, driven by strong performance in both its Orthopaedic Implants and MedSurg Equipment segments. This growth was fueled by increased unit volume, higher selling prices, and favorable foreign currency exchange rates. Stryker's strategic acquisitions, such as the Surgical Dynamics Inc. spinal implant business, further bolstered its product offerings and market position. Financially, Stryker demonstrated strong profitability, with net earnings increasing by 31% to $453.5 million. The company also managed its debt effectively, with total borrowings declining significantly. Looking ahead, Stryker expressed optimism for 2004, anticipating continued sales growth and a focus on investing in future business expansion, including potential acquisitions. The company's commitment to research and development, evidenced by increased R&D spending, and its expanding international presence highlight its strategy for sustained long-term growth and market leadership.

Key Highlights

1Stryker reported a 20% year-over-year increase in net sales, reaching $3.63 billion for the fiscal year 2003.

2Net earnings saw a substantial 31% increase, totaling $453.5 million, indicating strong profitability.

3The Orthopaedic Implants segment grew by 23% and the MedSurg Equipment segment grew by 18%, demonstrating broad-based growth across key business units.

4International sales increased by 24%, contributing significantly to overall revenue growth and highlighting the company's global reach.

5Research, development, and engineering expenses increased by 27% to $180.2 million, reflecting a commitment to innovation and future product development.

6The company successfully reduced its long-term debt, with total borrowings declining significantly from $501.7 million in 2002 to $26.1 million in 2003.

7Stryker provided a positive outlook for 2004, projecting diluted net earnings per share of approximately $2.68 and net sales growth of 16%.

STRYKER CORP Annual Report, Year Ended Dec 31, 2003

Summary

Key Highlights

Frequently Asked Questions